Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What NH guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 07 Nov 2026 | Narayana Hrudayalaya Limited filed the transcript of its Q2 FY27 earnings call held on November 02, 2026 for the quarter and half year ended September 30, 2026. On the India business, management said IP volumes rose 4% year-on-year, OP footfall rose about 12.5%, and ARPOB rose from INR17.5 million to INR19.5... NSE copy | No results filed since | ||
| 10 Aug 2026 | Narayana Hrudayalaya filed the transcript of its Q1 FY27 earnings call held on August 03, 2026, for the quarter ended June 30, 2026. Management said footfalls and realisations both contributed to India hospital revenue growth, with clinics contributing about 30% of total OPD footfalls and no meaningful bed... NSE copy | +16.6 % | +73.0 % | +6.6 % |
| 02 Jun 2026 | Narayana Hrudayalaya filed the transcript of its Q4 and FY26 earnings call held on May 26, 2026, and said the transcript is also on its website. On the India clinics and insurance business, management said losses of about INR 66 crore in FY26 reflect new clinics taking around 18 months to turn around and corporate... NSE copy | +5.7 % | +78.0 % | -5.4 % |
| 24 Feb 2026 | Narayana Hrudayalaya filed the transcript of its Q3 FY26 earnings call held on February 17, 2026, for the quarter ended December 31, 2025, and said it is also on the company website. Management (Venkatesh R.) said India realizations improved from transformation and payor mix initiatives, with volumes and occupancy... NSE copy | +16.2 % | +75.8 % | +4.5 % |
| 24 Nov 2025 | Narayana Hrudayalaya filed the transcript of its Q2 FY26 earnings call held on November 17, 2025, for the quarter and half year ended September 30, 2025. Dr. Anesh Shetty said insurance product uptake in Cayman is strong with most large employers moved or considering moving, and that a steady-state view on market... NSE copy | -33.7 % | +57.4 % | +0.9 % |
| 03 Nov 2025 | Narayana Hrudayalaya filed a revised investor presentation on its acquisition of UK-based Practice Plus Group Hospitals Limited, following its October 31, 2025 disclosure. The company acquired 100% of Practice Plus Group Hospitals Limited, described as the 5th largest private healthcare network in the UK and the... NSE copy | +30.0 % | +17.4 % | +14.5 % |
| 31 Oct 2025 | Narayana Hrudayalaya filed an investor presentation on its acquisition of UK-based Practice Plus Group Hospitals Limited, further to a disclosure made on October 30, 2025. The target is acquired 100% for about GBP 183 million, implying 9.2x FY25E EV/EBITDA on currently operational centers (adjusted for cash... NSE copy | +30.0 % | +17.4 % | +14.5 % |
| 11 Aug 2025 | Narayana Hrudayalaya filed the transcript of its Q1 FY26 earnings call held on August 4, 2025, for the quarter ended June 30, 2025; the transcript is also on the company website. Management said Cayman hospital patient volumes fell quarter on quarter due to early-stage volatility in the new hospital, and expects... NSE copy | +30.0 % | +17.4 % | +14.5 % |
| 02 Jun 2025 | Narayana Hrudayalaya filed the transcript of its Q4 FY25 earnings call held May 27, 2025, for the quarter and year ended March 31, 2025. Management said the Cayman hospital ramped up faster than expected, with new urgent care, trauma, obstetrics and gynecology departments; Anesh Shetty said about $45 million could... NSE copy | -2.7 % | +12.4 % | -6.0 % |
| 23 May 2025 | Board of Narayana Hrudayalaya Limited approved audited standalone and consolidated financial results for the year ended March 31, 2025, with an unmodified audit opinion from Deloitte Haskins & Sells LLP. Board recommended a final dividend of Rs. 4.50 per share for FY2024-25, subject to shareholder approval at the... NSE copy | +2.9 % | +15.3 % | -1.9 % |
| 24 Feb 2025 | Narayana Hrudayalaya Limited filed the transcript of its Q3 FY25 earnings conference call held on February 18, 2025, for the quarter ended December 31, 2024; the transcript is also on the company website. Management said the new Cayman hospital began outpatient services in early December 2024, with emergency,... NSE copy | +2.9 % | +15.3 % | -1.9 % |
Filings tagged as guidance, newest first (11 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 04 Nov 2026 | Legal or regulatory | Narayana Hrudayalaya Limited filed the NCLT, Bengaluru Bench order sanctioning the Scheme of Arrangement between its wholly owned subsidiary NH Integrated Care Private Limited (demerged company) and the company (resulting company) under Sections 230 to 232 of the Companies Act, 2013. The order was uploaded on the... NSE copy |
| 10 Aug 2026 | Legal or regulatory | Narayana Hrudayalaya filed the transcript of its Q1 FY27 earnings call held on August 03, 2026, for the quarter ended June 30, 2026. Management said footfalls and realisations both contributed to India hospital revenue growth, with clinics contributing about 30% of total OPD footfalls and no meaningful bed... NSE copy |
| 22 May 2026 | Legal or regulatory, Management change | Board of Narayana Hrudayalaya Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from Deloitte Haskins & Sells LLP. The Board recommended a final dividend of Rs. 4.50 per share for FY2026, subject to shareholder... NSE copy |
| 22 May 2026 | Management change | Narayana Hrudayalaya Limited filed the outcome of its board meeting held on May 22, 2026, approving audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from Deloitte Haskins & Sells LLP. The board recommended a final dividend of Rs.... NSE copy |
| 13 Feb 2026 | Legal or regulatory | Narayana Hrudayalaya Limited's board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 on February 13, 2026. Standalone revenue from operations for Q3 FY26 was ₹9,687.81 million, against ₹8,650.43 million a year earlier; standalone net profit... NSE copy |
| 13 Feb 2026 | Legal or regulatory | Board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (board meeting held February 13, 2026). Standalone Q3 FY26 revenue from operations was ₹9,687.81 million, against ₹8,650.43 million a year earlier; net profit was ₹757.37 million, against... NSE copy |
| 19 Jan 2026 | Credit rating | Narayana Hrudayalaya Limited filed intimation under Regulation 30 of SEBI LODR on credit rating revision by ICRA Limited, following an earlier intimation dated January 13, 2026. ICRA reaffirmed ratings at [ICRA]AA (Stable) for long-term instruments, [ICRA]AA (Stable)/[ICRA]A1+ for cash credit and working capital,... NSE copy |
| 13 Jan 2026 | Credit rating | Narayana Hrudayalaya Limited filed intimation under Regulation 30 of the SEBI LODR Regulations on credit ratings assigned by ICRA Limited, dated January 12, 2026. ICRA reaffirmed [ICRA]AA (Stable) on long-term bank facilities including term loan of Rs. 1,912.00 crore and cash credit of Rs. 100.00 crore, with... NSE copy |
| 12 Dec 2025 | Legal or regulatory | Narayana Hrudayalaya Limited's board approved, on December 12, 2025, a Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013 with NH Integrated Care Private Limited and their shareholders and creditors. The Scheme provides for demerger of the Clinical Services undertaking (10 clinics in... NSE copy |
| 12 Dec 2025 | Legal or regulatory | Narayana Hrudayalaya Limited's board approved, on December 12, 2025, a Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013 with its wholly owned subsidiary NH Integrated Care Private Limited and their shareholders and creditors. The Scheme provides for demerger of the Clinical Services... NSE copy |
| 14 Nov 2025 | Legal or regulatory | Narayana Hrudayalaya Limited filed the outcome of its board meeting held on November 14, 2025, approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with a limited review report from Deloitte Haskins & Sells LLP. Standalone revenue from operations... NSE copy |
| 14 Nov 2025 | Legal or regulatory | Board of Narayana Hrudayalaya Limited approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 at a meeting held November 14, 2025 (3:30 PM to 6:10 PM IST); the statutory auditor issued a limited review report with no matters to report. Standalone... NSE copy |
| 01 Aug 2025 | Legal or regulatory | Board meeting held August 1, 2025 approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a limited review report from Deloitte Haskins & Sells LLP. Standalone revenue from operations for the quarter ended June 30, 2025 was Rs 9,431.41 million, against Rs 8,717.61... NSE copy |
| 01 Aug 2025 | Legal or regulatory | Board of Narayana Hrudayalaya Limited approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 on August 01, 2025, with a limited review report from Deloitte Haskins & Sells LLP. Standalone revenue from operations for Q1 FY26 was Rs 9,431.41 million, against Rs 8,717.61... NSE copy |
| 25 Jun 2025 | Legal or regulatory | Narayana Hrudayalaya Limited intimated receipt of Observation Letters on the draft Scheme of Arrangement between its subsidiary Meridian Medical Research & Hospital Ltd (transferor) and the company (transferee), under Sections 230-232 of the Companies Act, 2013. BSE issued an observation letter with "no adverse... NSE copy |
| 24 Jun 2025 | Legal or regulatory | Narayana Hrudayalaya Limited intimated receipt of an Observation Letter from BSE Limited dated June 23, 2025, stating "No Adverse Observation" on the proposed Scheme of Arrangement between its subsidiary Meridian Medical Research & Hospital Ltd (transferor company) and the company (transferee company). The Board... NSE copy |
| 23 May 2025 | Legal or regulatory | Board of Narayana Hrudayalaya Limited approved audited standalone and consolidated financial results for the year ended March 31, 2025, with an unmodified audit opinion from Deloitte Haskins & Sells LLP. Board recommended a final dividend of Rs. 4.50 per share for FY2025, subject to shareholder approval at the 25th... NSE copy |
| 17 Feb 2025 | Legal or regulatory | Narayana Hrudayalaya Limited filed its integrated filing (financials) with unaudited standalone results for the quarter and nine months ended December 31, 2024, approved by the Board on February 14, 2025 and reviewed by Deloitte Haskins & Sells LLP. Q3 FY25 revenue from operations was ₹8,650.43 million (quarter... NSE copy |
| 24 Jan 2025 | Credit rating | Narayana Hrudayalaya Limited filed intimation under Regulation 30 of SEBI LODR on January 24, 2025 regarding credit ratings assigned by ICRA Limited. ICRA reaffirmed [ICRA]AA(Stable)/[ICRA]A1+ on bank facilities including Rs. 90 crore interchangeable instruments, Rs. 100 crore cash credit and Rs. 80 crore fund... NSE copy |
| 29 Nov 2024 | Legal or regulatory | Narayana Hrudayalaya Limited's board approved on November 29, 2024 a draft Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013 for amalgamation of its subsidiary Meridian Medical Research & Hospital Ltd into the company, subject to stock exchange, NCLT, regulatory, shareholder and creditor... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (20 in all). A list of what was filed, not a judgement of the company.